Insulin-like Growth Factor-1-and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma

Washington University in St. Louis, San Luis, Missouri, United States
Cancer Epidemiology Biomarkers & Prevention (Impact Factor: 4.32). 01/2009; 18(1):282-8. DOI: 10.1158/1055-9965.EPI-08-0778
Source: PubMed

ABSTRACT Insulin-like growth factor (IGF)-1 and interleukin (IL)-6 promote the proliferation and survival of multiple myeloma cells. Variation in genes related to IGF-1 and IL-6 signaling may influence susceptibility to multiple myeloma. To assess their etiologic role, we examined the association of 70 tagging single nucleotide polymorphisms (SNP) in seven IGF-1 and three IL-6 pathway genes with multiple myeloma risk in two prospective cohorts, the Nurses' Health Study and the Health Professionals Follow-up Study. Among the participants who provided DNA specimens, we identified 58 women and 24 men with multiple myeloma and matched two controls per case. We used multivariable logistic regression models to assess the association of the SNPs or tagged haplotypes with multiple myeloma risk. Several SNPs had suggestive associations with multiple myeloma based on large odds ratios (OR), although the corresponding omnibus P values were not more than nominally significant (i.e., at P < 0.05). These SNPs included rs1801278 in the gene encoding insulin receptor substrate-1 [IRS1; C/T versus C/C genotypes; OR, 4.3; 95% confidence interval (CI), 1.5-12.1] and three IL-6 receptor SNPs: rs6684439 (T/T versus C/C; OR, 2.9; 95% CI, 1.2-7.0), rs7529229 (C/C versus T/T; OR, 2.5; 95% CI, 1.1-6.0), and rs8192284 (C/C versus A/A; OR, 2.5, 95% CI, 1.1-6.0). Additional SNPs in genes encoding IGF-1, IGF binding protein-2, IRS2, and gp130 also showed suggestive associations with multiple myeloma risk. We conducted a large number of statistical tests, and the findings may be due to chance. Nonetheless, the data are consistent with the hypothesis that IGF-1- and IL-6-related gene variation influences susceptibility to multiple myeloma and warrant confirmation in larger populations.

Download full-text


Available from: Graham A Colditz, Jul 27, 2015
  • Source
    • "The Rotterdam Study found high levels of CRP to be associated with an increased risk of incident cancer with the strongest association for lung cancer (Siemes, Visser et al. 2006). IL-6 related gene variation was found to be associated with multiple myeloma in the Nurses' Health Study and the Health Professionals Follow-up Study (Birmann, Tamimi et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To review findings from major epidemiologic studies regarding risk factors for and consequences of elevated markers of inflammation in older adults. Most large, current epidemiologic studies of older adults have measured serum interleukin-6 (IL-6), C-reactive protein (CRP) and tumor necrosis factor alpha (TNF-alpha) and some studies also include more extensive batteries of measures including soluble receptors. There are few defined risk factors for the modest elevations in inflammatory markers seen with aging. These include visceral adiposity, lower sex steroid hormones, smoking, depression and periodontal disease. Of the markers assessed, IL-6 is most robustly associated with incident disease, disability and mortality. Though correlated with age, the etiology of elevated inflammatory markers remains incompletely defined. Inflammation, especially IL-6 may be a common cause of multiple age-related diseases or a final common pathway by which disease leads to disability and adverse outcomes in older adults. Future research targeting inflammation should examine these pathways.
    Ageing research reviews 12/2010; 10(3):319-29. DOI:10.1016/j.arr.2010.11.002 · 7.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A new architecture for constant-g<sub>m</sub>, rail-to-rail(R-R) input stages is presented that has less than 5% deviation in g<sub>m</sub> over the entire range of the input common-mode voltage. Furthermore, a new structure for folded cascode amplifier based on the use of a floating current source is presented. Employing these techniques a low-power operational transconductance amplifier (OTA) with 100 MHz unity-gain bandwidth, 106 dB gain, 60° phase margin, 2.65 V swing, and 6.4 nV/√Hz input-referred noise with R-R input common-mode range is realized in a 0.8 μm CMOS technology. This amplifier dissipates 10 mW from a 3V power supply.
    Low Power Electronics and Design, 2003. ISLPED '03. Proceedings of the 2003 International Symposium on; 09/2003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 10% of all hematologic cancers.1-2 MM is characterized by clonal proliferation of malignant plasma cells in the bone marrow, which secrete a homogeneous immunoglobulin product known as monoclonal (M) protein or paraprotein. Typical features of MM include osteolytic bone lesions, renal disease, anemia, hypercalcemia and immunodeficiency.3 The pathological development of MM is a multistep process and starts with the emergence of an asymptomatic premalignant stage of clonal plasma cell proliferation known as “monoclonal gammopathy of undetermined significance” (MGUS), occurring in about 3% of individuals above the age of 50. MGUS cells secrete monoclonal immunoglobulin (Ig) which may progress to smouldering MM and ultimately to symptomatic intramedullary and extramedullary multiple myeloma, or plasma cell leukemia; expressing the same Ig. Smouldering MM has a stable intramedullary tumor cell content of >10%, but no osteolytic lesions or other complications of malignant MM. Patients with MGUS have a risk to progress to myeloma or a related malignancy at a rate of 1% a year.4-5 The prevalence of both MGUS and MM increases markedly with age, and is slightly more common in men than in women. The incidence is about two-fold higher in African Americans than in Caucasians. The median length of survival after diagnosis is approximately 3-5 years.
Show more